Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry?
Indivior, a leader in opioid dependence therapies, reported a notable insider sale following a year of exceptional share price gains.
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry?
Overview
On June 11, 2026, Christian Heidbreder, Chief Scientific Officer at Indivior Pharmaceuticals (NASDAQ:INDV), reported the sale of 18,586 shares of common stock in an open-market transaction, as detailed in the SEC Form 4 filing.
Transaction value based on SEC Form 4 reported price ($38.06); post-transaction value based on June 11, 2026 market close ($38.13).
Details
* 1-year performance calculated using June 11, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
